Exagen Announces Acceptance of Five Abstracts at 2024 American College of Rheumatology Convergence
Exagen Inc. (Nasdaq: XGN) announced the acceptance of five abstracts at the 2024 American College of Rheumatology's (ACR) annual meeting, ACR Convergence 2024, scheduled for November 14-19, 2024, in Washington, D.C. The company's featured plenary presentation, in collaboration with Johns Hopkins University, will showcase a urinary biomarker panel for guiding precision management of Lupus Nephritis. Additional abstracts highlight Exagen's research on novel T Cell biomarkers for Lupus and anti-RA33 autoantibodies for rheumatoid arthritis, aimed at improving diagnostic sensitivity of the AVISE CTD platform.
The accepted abstracts cover topics such as predicting histologically active Lupus Nephritis, validating T Cell-bound C4d and T Cell Autoantibodies for SLE diagnosis, and exploring autoantibodies in seronegative rheumatoid arthritis. These presentations demonstrate Exagen's commitment to innovative research in rheumatologic care.
Exagen Inc. (Nasdaq: XGN) ha annunciato l'accettazione di cinque abstract per il meeting annuale del American College of Rheumatology (ACR), ACR Convergence 2024, in programma dal 14 al 19 novembre 2024 a Washington, D.C. La presentazione plenaria in evidenza della compagnia, in collaborazione con la Johns Hopkins University, presenterà un pannello di biomarker urinari per guidare la gestione di precisione della Nefrite Lupica. Ulteriori abstract evidenziano la ricerca di Exagen su novi biomarker T Cell per il Lupus e autoanticorpi anti-RA33 per l'artrite reumatoide, mirati a migliorare la sensibilità diagnostica della piattaforma AVISE CTD.
Gli abstract accettati trattano argomenti come la previsione della Nefrite Lupica istologicamente attiva, la validazione di C4d legato alle T Cell e degli autoanticorpi T Cell per la diagnosi del LES, e l'esplorazione degli autoanticorpi nell'artrite reumatoide seronegativa. Queste presentazioni dimostrano l'impegno di Exagen nella ricerca innovativa nella cura reumatologica.
Exagen Inc. (Nasdaq: XGN) anunció la aceptación de cinco resúmenes para la reunión anual del American College of Rheumatology (ACR), ACR Convergence 2024, programada del 14 al 19 de noviembre de 2024 en Washington, D.C. La presentación plenaria destacada de la empresa, en colaboración con la Universidad Johns Hopkins, presentará un panel de biomarcadores urinarios para guiar la gestión precisa de la Nefritis Lúpica. Resúmenes adicionales destacan la investigación de Exagen sobre nuevos biomarcadores T Cell para el Lupus y autoanticuerpos anti-RA33 para la artritis reumatoide, con el objetivo de mejorar la sensibilidad diagnóstica de la plataforma AVISE CTD.
Los resúmenes aceptados abordan temas como la predicción de la Nefritis Lúpica histológicamente activa, la validación de C4d unido a T Cell y autoanticuerpos T Cell para el diagnóstico de LES, y la exploración de autoanticuerpos en la artritis reumatoide seronegativa. Estas presentaciones demuestran el compromiso de Exagen con la investigación innovadora en el cuidado reumatológico.
Exagen Inc. (Nasdaq: XGN)는 2024년 미국 류마티스학회(ACR)의 연례 회의인 ACR Convergence 2024에 다섯 개 초록이 수락되었음을 발표했습니다. 이 회의는 2024년 11월 14일부터 19일까지 워싱턴 D.C.에서 열립니다. 존스 홉킨스 대학과 협력하여 진행되는 회사의 전체 발표에서는 루푸스 신염의 정밀 관리를 위한 요소 변별 바이오마커 패널이 소개됩니다. 추가 초록에서는 루푸스에 대한 새로운 T 세포 바이오마커와 류마티스 관절염을 위한 항 RA33 자가항체에 대한 Exagen의 연구도 강조되어, AVISE CTD 플랫폼의 진단 감도를 개선하는 데 초점을 맞추고 있습니다.
수락된 초록은 조직학적으로 활동적인 루푸스 신염 예측, SLE 진단을 위한 T 세포 결합 C4d 및 T 세포 자가항체의 검증, 그리고 혈청 음성 류마티스 관절염에서 자가항체 탐색과 같은 주제를 다룹니다. 이러한 발표는 류마티스 치료에서의 혁신적인 연구에 대한 Exagen의 헌신을 보여줍니다.
Exagen Inc. (Nasdaq: XGN) a annoncé l'acceptation de cinq résumés pour la réunion annuelle du American College of Rheumatology (ACR), ACR Convergence 2024, prévue du 14 au 19 novembre 2024 à Washington, D.C. La présentation plénière de l'entreprise, en collaboration avec l'Université Johns Hopkins, présentera un panel de biomarqueurs urinaires pour guider la gestion de précision de la Néphrite Lupique. Des résumés supplémentaires mettent en avant la recherche d'Exagen sur de nouveaux biomarqueurs T Cell pour le Lupus et des autoanticorps anti-RA33 pour l'arthrite rhumatoïde, visant à améliorer la sensibilité diagnostique de la plateforme AVISE CTD.
Les résumés acceptés couvrent des sujets tels que la prédiction de la Néphrite Lupique histologiquement active, la validation des C4d liés aux T Cell et des autoanticorps T Cell pour le diagnostic du LES, ainsi que l'exploration des autoanticorps dans l'arthrite rhumatoïde séro-négative. Ces présentations montrent l'engagement d'Exagen envers la recherche innovante dans les soins rhumatologiques.
Exagen Inc. (Nasdaq: XGN) gab die Annahme von fünf Abstracts für die jährliche Tagung des American College of Rheumatology (ACR) bekannt, die ACR Convergence 2024 heißt und vom 14. bis 19. November 2024 in Washington, D.C. stattfindet. Die Hauptpräsentation des Unternehmens, in Zusammenarbeit mit der Johns Hopkins University, wird ein Urinen-Biomarker-Paneel zur präzisen Steuerung der Lupusnephritis-Management vorstellen. Zusätzliche Abstracts heben Exagens Forschung zu neuen T-Zellen-Biomarkern für Lupus und anti-RA33-Autoantikörpern bei rheumatoider Arthritis hervor, die darauf abzielen, die diagnostische Sensitivität der AVISE CTD-Plattform zu verbessern.
Die akzeptierten Abstracts behandeln Themen wie die Vorhersage von histologisch aktiver Lupusnephritis, die Validierung von T-Zellen-gebundenem C4d und T-Zellen-Autoantikörpern für die SLE-Diagnose sowie die Erforschung von Autoantikörpern bei seronegativer rheumatoider Arthritis. Diese Präsentationen zeigen Exagens Engagement für innovative Forschung in der rheumatologischen Versorgung.
- Acceptance of five abstracts at a major rheumatology conference, showcasing Exagen's research prowess
- Collaboration with Johns Hopkins University on a plenary presentation, potentially enhancing company credibility
- Development of novel biomarkers for Lupus and rheumatoid arthritis, potentially improving diagnostic accuracy
- Potential improvement in the diagnostic sensitivity of the AVISE CTD platform, which could lead to increased market adoption
- None.
Insights
The acceptance of five abstracts at the 2024 ACR Convergence highlights Exagen's significant progress in autoimmune testing research. The plenary presentation on a urinary biomarker panel for Lupus Nephritis could be a game-changer in precision management. This, along with novel T Cell biomarkers for Lupus and anti-RA33 autoantibodies for rheumatoid arthritis, demonstrates potential improvements in diagnostic sensitivity of the AVISE CTD platform.
Key points:
- Urinary biomarker panel may improve Lupus Nephritis management
- T Cell-bound C4d and T Cell Autoantibodies show enhanced accuracy for SLE diagnosis
- Combination of anti-RA33, anti-CarP and anti-PAD4 autoantibodies could improve seronegative RA diagnosis
- CB-CAPs demonstrate added value in SLE diagnosis
While these advancements are promising, investors should note that research presentations don't immediately translate to marketable products or revenue. The long-term potential is significant, but short-term impact on Exagen's
CARLSBAD, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, announced today the acceptance of five abstracts at the 2024 American College of Rheumatology’s (ACR) annual meeting, ACR Convergence 2024, being held November 14-19, 2024, at the Walter E. Washington Convention Center in Washington, D.C.
Exagen’s featured plenary presentation, in collaboration with Johns Hopkins University, will highlight a urinary biomarker panel that holds the potential to guide precision management of Lupus Nephritis, addressing a critical need for rheumatologists. Additional abstracts highlight Exagen’s innovative research on novel T Cell biomarkers for Lupus and anti-RA33 autoantibodies for rheumatoid arthritis, both of which will significantly improve diagnostic sensitivity of the AVISE CTD platform.
“Exagen’s commitment to innovative research is showcased in our abstracts and validates our continued efforts to bring novel biomarkers to the forefront of rheumatologic care,” said Dr. Andrew Concoff, Chief Innovation Officer of Exagen. “We look forward to sharing our findings with the rheumatology community, with the goal of furthering patient care.”
Below is the list of accepted abstracts, with links to each:
Plenary Session in Collaboration with Johns Hopkins
Plenary Session | Presented by Andrea Fava | Abstract #1642
Title: A Urinary Biomarker Panel to Predict the Probability of Histologically Active Lupus Nephritis
Session Title: Plenary II
Session Date and Time: Sunday, November 17th, 2024, from 9:00 a.m. – 9:15 a.m. ET
Novel Biomarker Development Abstracts
Poster Presentation | Presented by Vasileios Kyttaris | Abstract #1490
Title: Multi-centered Clinical Validation of T Cell-bound C4d (TC4d) and T Cell Autoantibodies (TIgG and TIgM): Sensitive and Specific Biomarkers of SLE with Enhanced Accuracy Compared to Conventional SLE Tests
Session Title: SLE – Diagnosis, Manifestations, & Outcomes, Poster II
Session Date and Time: Sunday, November 17th, 2024, from 10:30 a.m. – 12:30 p.m. ET
Poster Presentation | Presented by Andrew Concoff| Abstract #2233
Title: Maximizing Diagnostic Sensitivity: Combined Anti-RA33, Anti-CarP, and Anti-PAD4 Autoantibodies in Seronegative Rheumatoid Arthritis
Session Title: RA – Diagnosis, Manifestations, & Outcomes, Poster III
Session Date and Time: Monday, November 18th, 2024, from 10:30 a.m. – 12:30 p.m. ET
Poster Presentation | Presented by Andrew Concoff| Abstract #2232
Title: Anti-RA33 Autoantibodies Are Unique, Sensitive Biomarkers for the Identification of Seronegative Rheumatoid Arthritis in a U.S. Cohort
Session Title: RA – Diagnosis, Manifestations, & Outcomes, Poster III
Session Date and Time: Monday, November 18th, 2024, from 10:30 a.m. – 12:30 p.m. ET
Clinical Evidence Reinforcing CB-CAPs Superior Performance Compared to Conventional Tests
Poster Presentation | Presented by Andrew Concoff| Abstract #0608
Title: Systematic Analysis Demonstrates the Added Value of CB-CAPs to SLE Diagnosis in a Large Validation Cohort
Session Title: SLE – Diagnosis, Manifestations, & Outcomes, Poster I
Session Date and Time: Saturday, November 16th, 2024, from 10:30 a.m. – 12:30 p.m. ET
About Exagen Inc.
Exagen Inc. (Nasdaq: XGN) is a leading provider of autoimmune diagnostics, committed to transforming care for patients with chronic and debilitating autoimmune conditions. Based in San Diego County, Calif., Exagen’s mission is to provide clarity in autoimmune disease decision making and improve clinical outcomes through its innovative testing portfolio. The company’s flagship product, AVISE® CTD, enables clinicians to more effectively diagnose complex autoimmune conditions such as lupus, rheumatoid arthritis, and Sjögren’s syndrome earlier and with greater accuracy. Exagen’s laboratory specializes in the testing of rheumatic diseases, delivering precise and timely results, supported by a full suite of AVISE-branded tests for disease diagnosis, prognosis, and monitoring. With a focus on research, innovation, education, and patient-centered care, Exagen is dedicated to addressing the ongoing challenges of autoimmune disease management. For more information, visit Exagen.com or follow @ExagenInc on X.
Forward Looking Statements
Exagen cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on Exagen's current beliefs and expectations. The inclusion of forward-looking statements should not be regarded as a representation by Exagen that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Exagen’s business, including, without limitation Exagen’s goals, strategies and ambitions; potential future financial and business performance; the potential for Exagen’s research to lead to positive impacts to patients; the potential for Exagen’s research to lead to new or improved testing products; the potential utility and effectiveness of Exagen’s services and testing solutions; updates to be made to AVISE® CTD; potential shareholder value and growth and 2024 guidance. The inclusion of forward-looking statements should not be regarded as a representation by Exagen that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Exagen’s business, including, without limitation: delays in reimbursement and coverage decisions from Medicare and third-party payors and in interactions with regulatory authorities, and delays in ongoing and planned clinical trials involving its tests; changes in laws and regulations related to Exagen’s regulatory requirements; Exagen’s commercial success depends upon attaining and maintaining significant market acceptance of its testing products among rheumatologists, patients, third-party payors and others in the medical community; Exagen’s ability to successfully execute on its business strategies; third-party payors not providing coverage and adequate reimbursement for Exagen’s testing products, including Exagen’s ability to collect on funds due; Exagen’s ability to obtain and maintain intellectual property protection for its testing products; regulatory developments affecting Exagen’s business; and other risks described in Exagen’s prior press releases and Exagen’s filings with the Securities and Exchange Commission (“SEC”), including under the heading “Risk Factors” in Exagen’s Annual Report on Form 10-K for the year ended December 31, 2023 and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Exagen undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Contact:
Ryan Douglas
Exagen Inc.
ir@exagen.com
760.560.1525
FAQ
What is the significance of Exagen's (XGN) abstracts being accepted at ACR Convergence 2024?
What new biomarkers is Exagen (XGN) presenting at ACR Convergence 2024?
When and where is ACR Convergence 2024 taking place?
What is the focus of Exagen's (XGN) plenary presentation at ACR Convergence 2024?
